Biofrontera AG

B8F

Equity

ISIN DE0006046113 / Valor 2261450

Xetra (2024-05-13)

EUR 0.31-2.50%

Biofrontera AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Biofrontera AG is a Germany-based biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The company's main product is the combination of Ameluz®, a topical prescription drug, and a proprietary red-light lamp for photodynamic therapy of certain superficial skin cancers and their precursors. In addition to Ameluz®, Biofrontera also sells the dermocosmetics series Belixos® in the EU, offering specialized care for damaged or diseased skin. Founded in 1997, Biofrontera is listed on the Frankfurt Stock Exchange and has received approvals for its products in both Europe and the United States.

Summarized from source with an LLMView SourceSector:

Revenue Growth

In 2023, Biofrontera AG reported a significant increase in revenue, reaching 32,249 TEUR. This represents a notable rise from the 25,738 TEUR recorded in 2022, indicating a strong year-over-year growth in sales.

Operational Performance

Biofrontera AG's operating income showed a remarkable improvement in 2023, with the company achieving 4,782 TEUR compared to just 1,591 TEUR in 2022. This improvement in operational efficiency highlights the company's successful cost management and operational strategies.

EBITDA and EBIT

The company's EBITDA in 2023 stood at 5,923 TEUR, a significant increase from 1,869 TEUR in 2022. Similarly, EBIT rose to 5,132 TEUR in 2023 from 1,124 TEUR in the previous year, demonstrating enhanced profitability and operational control.

Research and Development Costs

Biofrontera AG continued to invest in innovation, with research and development costs amounting to 7,846 TEUR in 2023. This is an increase from 7,128 TEUR in 2022, reflecting the company's commitment to advancing its product offerings.

Pre-Tax Loss

Despite the positive trends in operational performance and revenue, Biofrontera AG reported a pre-tax loss of 2,127 TEUR in 2023. This situation marks a significant improvement, however, compared to the substantial pre-tax loss of 43,210 TEUR in 2022.

Summarized from source with an LLMView Source

Key figures

-70.0%1Y

-86.7%3Y

-95.0%5Y

Performance

115%1Y

79.8%3Y

76.4%5Y

Volatility